Cygnus Capital Advisors’s TherapeuticsMD TXMD Stock Holding History

Cygnus Capital Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,069	Closed	-$18K	–	105
2026 Q1	$18K	Buy	+9,069	New	+$20.4K	0.01%	89

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cygnus Capital Advisors's TXMD Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of TherapeuticsMD (TXMD) in Q2 2026, closing a stake of 9,069 shares — an estimated $18K sold.

Cygnus Capital Advisors first reported a position in TXMD in Q1 2026 and held it in 1 quarter. The position peaked at $18K in Q1 2026. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

Cygnus Capital Advisors reported no remaining TherapeuticsMD position as of Q2 2026 after selling out during the quarter.
Cygnus Capital Advisors sold 9,069 TherapeuticsMD shares in Q2 2026, an estimated $18K.
Cygnus Capital Advisors first reported a position in TherapeuticsMD in Q1 2026 and held it in 1 quarter.
Cygnus Capital Advisors's TherapeuticsMD position peaked at $18K in Q1 2026.
44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.